Supplementary Material

Article Title: Preventive Effects of Lamotrigine in Bipolar II Versus Bipolar I Disorder

Author(s): Takeshi Terao, MD, PhD; Atsuko Ishida, BS; Toshifumi Kimura, MS; Masao Yarita, MS; and Terufumi Hara, BS

DOI Number: 10.4088/JCP.16m11404

List of Supplementary Material for the article

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary eTable 1: Mean daily dose of lamotrigine, and concomitant drug for Bipolar Disorder

Patient background factor/category		Bipolar I (n=191)		Bipolar II (n=399)	
Mean daily dose (mg/d) (maintenance dose)	≤50	31	(16.2)	51	(12.8)
	>50 to ≤100	48	(25.1)	84	(21.1)
	>100 to ≤150	15	(7.9)	49	(12.3)
	>150 to ≤200	46	(24.1)	109	(27.3)
	>200 to ≤250	8	(4.2)	18	(4.5)
	>250 to ≤300	9	(4.7)	12	(3.0)
	>300 to ≤350	1	(0.5)	3	(0.8)
	>350 to ≤400	4	(2.1)	8	(2.0)
	Unknown	29	(15.2)	65	(16.3)
	Min–max	25.0-400.0		21.0-400.0	
	Mean±SD	137.6±82.1		142.7±78.2	
	Median	106.8		136.2	
	Mode	100.0		200.0	
Concomitant medications					
Mood stabilizers		122	(63.9)	171	(42.9)
Lithium		91	(47.6)	105	(26.3)
Valproate sodium		48	(25.1)	66	(16.5)
Carbamazepine		8	(4.2)	12	(3.0)
Typical antipsychotics		26	(13.6)	42	(10.5)
Sulpiride		3	(1.6)	22	(5.5)
Levomepromazine maleate		9	(4.7)	14	(3.5)
Atypical antipsychotics		98	(51.3)	126	(31.6)
Olanzapine		37	(19.4)	41	(10.3)
Aripiprazole		33	(17.3)	50	(12.5)
Quetiapine		29	(15.2)	38	(9.5)
Risperidone		13	(6.8)	4	(1.0)
Antidepressants		55	(28.8)	195	(48.9)
Duloxetine hydrochloride		2	(1.0)	53	(13.3)
Mirtazapine		8	(4.2)	48	(12.0)
Paroxetine hydrochloride hydrate		11	(5.8)	44	(11.0)
Fluvoxamine maleate		8	(4.2)	28	(7.0)
Sertraline hydrochloride		5	(2.6)	28	(7.0)
Milnacipran hydrochloride		7	(3.7)	11	(2.8)
Escitalopram oxalate		3	(1.6)	7	(1.8)
Amoxapine		6	(3.1)	6	(1.5)

[a]Values expressed as n (%) unless otherwise noted.

Supplementary eTable 2: Frequency of ADRs (≥3% by SOC) (Safety Analysis Set)

	Bipolar I (n=191)		Bipolar II (n=399)	
No. of patients with ADRs	42		87	
No. of ADRs	54		132	
Incidence rate of ADRs (%)	22·0		21·8	
Type of ADRs	No. of patients with ADRs			
Psychiatric disorders	10	(5·2)	13	(3·3)
Aggression	1	(0·5)	0	(0·0)
Anger	1	(0·5)	3	(0·8)
Anxiety	1	(0·5)	1	(0·3)
Depression	0	(0·0)	1	(0·3)
Dissociative disorder	0	(0·0)	1	(0·3)
Hypomania	1	(0·5)	1	(0·3)
Insomnia	1	(0·5)	2	(0·5)
Intentional self-injury	0	(0·0)	1	(0·3)
Irritability	4	(2·1)	1	(0·3)
Mania	0	(0·0)	2	(0·5)
Panic attack	0	(0·0)	1	(0·3)
Suicidal ideation	2	(1·1)	1	(0·3)
Depressive symptom	0	(0·0)	1	(0·3)
Somatic hallucination	0	(0·0)	1	(0·3)
Nervous system disorders	4	(2·1)	17	(4·3)
Akathisia	1	(0·5)	0	(0·0)
Dizziness	0	(0·0)	5	(1·3)
Dizziness postural	0	(0·0)	1	(0·3)
Headache	1	(0·5)	3	(0·8)
Hypersomnia	0	(0·0)	2	(0·5)
Hypoaesthesia	0	(0·0)	1	(0·3)
Migraine	0	(0·0)	1	(0·3)
Neuralgia	0	(0·0)	1	(0·3)
Paraesthesia	0	(0·0)	1	(0·3)
Sedation	0	(0·0)	1	(0·3)
Somnolence	1	(0·5)	5	(1·3)
Tremor	1	(0·5)	2	(0.5)

[a]Values expressed as n (%) unless otherwise noted.

Skin and subcutaneous tissue disorders	22	(11·5)	46	(11·5)
Chloasma	0	(0·0)	1	(0·3)
Cold sweat	0	(0·0)	1	(0·3)
Drug eruption	2	(1·1)	3	(0·8)
Eczema	0	(0·0)	1	(0·3)
Erythema	1	(0·5)	1	(0·3)
Erythema multiforme	0	(0·0)	1	(0·3)
Pruritus	3	(1·6)	4	(1·0)
Purpura	1	(0·5)	0	(0·0)
Rash	17	(8·9)	34	(8·5)
Skin erosion	0	(0·0)	1	(0·3)
Skin exfoliation	0	(0·0)	1	(0·3)
Stevens-Johnson Syndrome	0	(0·0)	1	(0·3)
Swelling face	0	(0·0)	1	(0·3)
Drug reaction with eosinophilia and systemic symptoms	0	(0·0)	1	(0·3)

[a]Values expressed as n (%) unless otherwise noted.

(MedDRA/J version 18.1)

MedDRA=Medical Dictionary for Regulatory Activities. SOC=System Organ Class.